Efficacy and safety of oxiracetam in patients with vascular cognitive impairment: A multicenter, randomized, double-blinded, placebo-controlled, phase IV clinical trial

Oxiracetam may have a modest effect on preventing cognitive decline. Exercise can also enhance cognitive function. This trial aims to investigate the effect of oxiracetam on post-stroke cognitive impairment and explore whether this effect is modified by exercise. Furthermore, the mechanisms that med...

Full description

Saved in:
Bibliographic Details
Published in:Contemporary clinical trials 2023-03, Vol.126, p.107108-107108, Article 107108
Main Authors: Lim, Jae-Sung, Lee, Juneyoung, Kang, Yeonwook, Park, Hyun-Tae, Kim, Dong-Eog, Cha, Jae-Kwan, Park, Tai Hwan, Heo, Jae-Hyuk, Lee, Kyung Bok, Park, Jong-Moo, Oh, Mi Sun, Kim, Eung-Gyu, Chang, Dae-Il, Heo, Sung Hyuk, Park, Man-Seok, Park, HyunYoung, Yi, SangHak, Lee, Yeong Bae, Park, Kwang-Yeol, Lee, Soo Joo, Kim, Jae Guk, Lee, Jun, Cho, Kyung-Hee, Rha, Joung-Ho, Kim, Yeong-In, Lee, Jun Hong, Choi, Jay Chol, Oh, Kyung-Mi, Kwon, Jee-Hyun, Kim, Chulho, Park, Jong-Ho, Jung, Keun-Hwa, Sung, Sang Min, Chung, Jong-Won, Lee, Yong-Seok, Kim, Hahn Young, Cho, Hyun-Ji, Park, Jeong Wook, Moon, Won-Jin, Bae, Hee-Joon
Format: Article
Language:English
Subjects:
Clinical trial
Cognitive Dysfunction - drug therapy
Double-Blind Method
Exercise
Functional MRI
Humans
Oxiracetam
Pyrrolidines - therapeutic use
Quality of Life
Stroke
Treatment Outcome
Vascular cognitive impairment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Oxiracetam may have a modest effect on preventing cognitive decline. Exercise can also enhance cognitive function. This trial aims to investigate the effect of oxiracetam on post-stroke cognitive impairment and explore whether this effect is modified by exercise. Furthermore, the mechanisms that mediate this effect will be investigated through a neural network analysis. This is a multicenter, randomized, double-blind, placebo-controlled phase IV trial. Patients who complained of cognitive decline 3 months after stroke and had a high risk of cognitive decline were eligible. Patients were randomly assigned to receive either 800 mg of oxiracetam or placebo twice daily for 36 weeks. After randomization, a predetermined exercise protocol was provided to each participant, and the degree of physical activity was assessed using wrist actigraphy at 4, 12, 24, and 36 weeks. Resting-state functional MRI was obtained in baseline and 36-week follow-up. Co-primary endpoints are changes in the Mini-Mental State Examination and Clinical Dementia Rating-Sum of Boxes. Secondary endpoints include changes in the NINDS-CSN VCIHS-Neuropsychology Protocol, Euro QoL, patient's global assessment, and functional network connectivity. If there is a significant difference in physical activity between the two groups, the interaction effect between physical activity and the treatment group will be examined. A total of 500 patients were enrolled from February 2018, and the last patient's final follow-up was completed in September 2022. This trial is meaningful not only to prove the efficacy of oxiracetam, but also evaluate whether exercise can modify the effects of medication and how cognitive function can be restored. Trial registrationhttp://cris.nih.go.kr (KCT0005137).
ISSN:1551-7144
1559-2030
DOI:10.1016/j.cct.2023.107108